Insider Transactions in Q3 2024 at Altimmune, Inc. (ALT)
Insider Transaction List (Q3 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Aug 19
2024
|
David Drutz Director |
SELL
Open market or private sale
|
Indirect |
16,011
-14.28%
|
$96,066
$6.91 P/Share
|
|
Aug 19
2024
|
David Drutz Director |
BUY
Exercise of conversion of derivative security
|
Indirect |
41,750
+27.06%
|
$83,500
$2.55 P/Share
|
|
Jul 31
2024
|
M Scot Roberts Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
650
+1.48%
|
$3,250
$5.41 P/Share
|
|
Jul 31
2024
|
Andrew Shutterly Acting Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,259
+9.97%
|
$6,295
$5.41 P/Share
|
|
Jul 31
2024
|
Matthew Scott Harris Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,486
+2.63%
|
$7,430
$5.41 P/Share
|
|
Jul 31
2024
|
Raymond M Jordt Chief Business Officer |
BUY
Grant, award, or other acquisition
|
Direct |
917
+5.89%
|
$4,585
$5.41 P/Share
|